Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920266 · ClinicalTrials.gov registry record · NA
Validity of Smart Cap and Smart Sweat Patch
A NA study of Fluid Intake in Athletes and Sweating Rate in Athletes, sponsored by PepsiCo Global R&D.
- Completed
- Registry status
- NA
- Development phase
- 173
- Enrollment target
- 3
- Study locations
NCT04920266: Completed NA study of Fluid Intake in Athletes and Sweating Rate in Athletes, sponsored by PepsiCo Global R&D.
NCT04920266 is a NA study of Fluid Intake in Athletes and Sweating Rate in Athletes that has completed, run by PepsiCo Global R&D. The registered enrollment target is 173 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04920266, a NA study of Fluid Intake in Athletes and Sweating Rate in Athletes, has completed, sponsored by PepsiCo Global R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 173 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main objectives are to determine the validity of a Smart Cap in measuring fluid intake during running and fitness exercise and the validity of a Smart Sweat Patch in measuring sweat rate and sweat chloride concentration during outdoor cycling, running, and fitness exercise. A secondary objective is to compare regional sweating rate and sweat electrolyte concentrations (sodium, chloride, and potassium) on contralateral arms with vs. without tattoos.
Primary Outcome
Smart Cap (sensor) versus Reference method (bottle weight)
Conditions Studied
Interventions
- DEVICE Smart Cap, running and fitness exercisers only
- DEVICE Sweat Patch, all subjects- running, fitness, cycling
- DEVICE Reference sweat patch, all subjects - running, fitness, cycling
- OTHER Bottle Scale, all subjects - running, fitness, cycling
Study Locations (3)
Illinois
- Gatorade Sports Science Institute (GSSI), 617 West Main Street - Barrington
- Grant Park, 337 E Randolph St - Chicago
- Cuba Marsh Forest Preserve, 24205 Cuba Rd - Deer Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2022-08-25 |
| Phase | NA |
What the finished NCT04920266 record still lists
NCT04920266 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Fluid Intake in Athletes appearing as the primary indexed condition, and to 4 interventions - of which Smart Cap, running and fitness exercisers only is the first listed.
NCT04920266 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04920266 about?
NCT04920266 is a clinical study titled "Validity of Smart Cap and Smart Sweat Patch". The main objectives are to determine the validity of a Smart Cap in measuring fluid intake during running and fitness exercise and the validity of a Smart Sweat Patch in measuring sweat rate and sweat chloride concentration during outdoor cycling, running, and fitness exercise. A secondary objective...
What is the current status of trial NCT04920266?
This trial is currently completed. It is a NA study. The enrollment target is 173 participants. The study started on 2021-06-08. Estimated completion is 2022-08-25.
What conditions does trial NCT04920266 study?
This clinical trial studies the following conditions: Fluid Intake in Athletes, Sweating Rate in Athletes, Sweat Chloride Concentration in Athletes.
What interventions are being tested in trial NCT04920266?
The interventions under investigation include: Smart Cap, running and fitness exercisers only (DEVICE), Sweat Patch, all subjects- running, fitness, cycling (DEVICE), Reference sweat patch, all subjects - running, fitness, cycling (DEVICE), Bottle Scale, all subjects - running, fitness, cycling (OTHER).
Who is sponsoring clinical trial NCT04920266?
This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04920266 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04920266's enrollment target sits among peer trials
173 611th of 2000 higher than 1,389 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI